Exelixis | EXEL - Interest Expense On Debt


Exelixis reported $23.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2023.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Akebia Therapeutics 362.52M 357.69M Mar/2026
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Bayer EUR 675M 87M Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Cytokinetics USD 33.34M 3M Mar/2026
Eisai JPY 1.55B 117M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Exelixis USD 23.4M 3.9M Sep/2023
Genmab DKK 10M 27M Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 479M 67M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sanofi EUR -25M 99.78M Dec/2025
Takeda JPY 43.65B 79.98B Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Xencor USD 4.7M 2.65M Mar/2026